# Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer

> **NCT01015521** · PHASE2 · WITHDRAWN · sponsor: **Tigris Pharmaceuticals** · enrollment: 50 (estimated)

## Conditions studied

- Breast Neoplasm

## Interventions

- **DRUG:** Aminoflavone Prodrug

## Key facts

- **NCT ID:** NCT01015521
- **Lead sponsor:** Tigris Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-04
- **Primary completion:** 2012-12
- **Final completion:** —
- **Target enrollment:** 50 (ESTIMATED)
- **Why stopped:** Study was not initiated as planned
- **Last updated:** 2010-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01015521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01015521, "Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01015521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*